Delivra Health Brands Third Quarter 2025 Earnings: CA$0.013 loss per share (vs CA$0.009 loss in 3Q 2024)

Delivra Health Brands (CVE:DHB) Third Quarter 2025 Results

Key Financial Results

• Revenue: CA$3.10m (flat on 3Q 2024).
• Net loss: CA$422.0k (loss widened by 50% from 3Q 2024).
• CA$0.013 loss per share (further deteriorated from CA$0.009 loss in 3Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Delivra Health Brands Earnings Insights

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in Canada.

Performance of the Canadian Pharmaceuticals industry.

The company's shares are down 11% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for Delivra Health Brands you should be aware of, and 2 of them shouldn't be ignored.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.